welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Summit announces PhaseOut DMD did not meet primary endpoint

Summit Therapeutics announced today that PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid.

Based on this outcome, the Company is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures. Summit will now focus its operations on the development of its pipeline of new mechanism antibiotics. The Company’s lead product candidate, ridinilazole, is expected to enter Phase 3 clinical trials for the treatment of C. difficile infection in Q1 2019.

Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint